

A Heritage of Healing


A Proven Biologic Solution for Peripheral Vascular Reconstruction

VASCU-GUARD Peripheral Vascular Patch is an Off-the-shelf Biologic Solution that:

- Provides high levels of biocompatibility¹
 - Low Gluteraldehyde levels under 4 ppm²
 - Does not promote mineralization or calcification*3
 - Supports endothelialization*4,5
- Resists suture line bleeding⁶
- Allows immediate intra-operative duplex⁶
- Is easy to handle and suture, similar to autologous vein⁶

VASCU-GUARD Patch

Supports reapproximation around suture (polypropylene 6–0)⁷





A Track Record That Speaks for Itself

As part of the Baxter TISSUE-GUARD Family of Products, the VASCU-GUARD Patch has over 862,885 patches sold and has a 20 year clinical history,⁸ which:

- Has shown a low incidence of restenosis as reported in published studies⁹⁻¹¹
- Helps provide long term patency rates and minimal thrombosis, aneurysm or pseudoaneurysm formation*4,*5,9,13
- Has shown a low adverse event rate (0.01%)⁸

*Preclinical results may not correlate to results in humans For Important Risk Information, please see back page.

VASCU-GUARD Patch Surgical Applications¹²

- Carotid Endarterectomy
- Profundaplasty
- Arteriovenous Access Revisions
- Femoral, Iliac, Renal and Tibial Patching







Available in a Variety of Sizes

VASCU-GUARD patch is easily trimmed to desired shape and size

Product Code: VG0106N Size: 1 cm >	x 6 cm Product Code: VG0209N	Size: 2 cm x 9 cm
Product Code: VG0110N	Size: 1 cm x 10 cm	t Code: VG0108N Size: 0.8 cm x 8 cm (tapered end)

Indications For Use:

For use in peripheral vascular reconstruction including the carotid, renal, iliac, femoral, profunda and tibial blood vessels and arteriovenous access revisions.

Contraindications:

VASCU-GUARD is not designed, sold or intended for use except as indicated.

Adverse Reactions:

Failure to rinse the product may result in a sterile inflammatory reaction.

Rx Only. For safe and proper use of this device refer to the complete Instructions for Use.

References

- 1. Data on File. Baxter Healthcare Corporation, V-0144.
- 2. Data on File. Baxter Healthcare Corporation, DS-1011 and DS-1012.
- 3. Data on File. Baxter Healthcare Corporation, SI-0021 and SI-0021R.
- 4. Li X, Jadlowiec C, Guo Y, et al. Pericardial patch angioplasty heals via an ephrin-B2 and CD34 positive cell mediated mechanism. PLoS One. 2012;7(6):1-8.
- 5. Data on File, 2003. Baxter Healthcare Corporation, SI-0020 and SI-0020R.
- 6. Biasi GM, Sternjakob S, Mingazzini PM, et al. Nine-year experience of bovine pericardium patch angioplasty during carotid endarterectomy. J Vasc Surg. 2002;36:271-277.
- 7. Biasi GM, Mingazzini P, Baronio L, et al. Processed bovine pericardium as patch angioplasty for carotid endarterectomy: a preliminary report. Cardiovasc Surg.
- 1996;4(5):591-5.
 Data on file. Baxter Healthcare Corporation. TGCS2013.
- 9. Ho KJ, Nguyen LL, Menard MT. Intermediate-term outcome of carotid endarterectomy with bovine pericardial patch closure compared with dacron patch and primary closure. J Vasc Surg. 2012;55(3):708-14.
- 10. Kim G, Kwon T, Cho Y, et al. Carotid endarterectomy with bovine patch angioplasty: a preliminary report. Cardiovascular Surg. 2001;9(5):458-462.
- 11. Neuhauser B, Oldenburg WA. Polyester vs bovine pericardial patching during carotid endarterectomy: early neurologic events and incidence of restenosis. Cardiovascular Surg. 2003;11(6):465-470.
- 12. VASCU-GUARD Peripheral Vascular Patch Instructions for Use. MS-0722001D.
- 13. Grimsley BR, Wells JK, Peral GJ, et al. Bovine pericardial patch angioplasty in carotid endarterectomy. Am Surg. 2001;67(9):890-5.

-

Synovis Life Technologies, Inc. A subsidiary of Baxter International Inc. 2575 University Ave W. St. Paul, MN 55114-1024 USA 651.796.7300



Baxter International Inc. One Baxter Parkway Deerfield, Illinois 60015 For questions or ordering information, please call 888-229-0001. www.baxterbiosurgery.com

Baxter, Tissue-Guard, Vascu-Guard and the Vascu-Guard logo are trademarks of Baxter International Inc., or its subsidiaries.

USMP/MG98/15-0003a (1) 7/2015